Locally Advanced or Metastatic Pancreatic Cancer Clinical Trial
Official title:
A Phase II Randomized Study of SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer
A Phase II Randomized Study.Primary objective:to investigate the 6-month progression-free survival (PFS) rate i patients receiving SLOG or mFLFIRINOX as a first-line treatment for locally advanced and metastatic pancreatic cancer.
A total of 130 patients (65patients in each arm) will be calculated, based on the assumption of a 6-month PFS rate of 45% with mFOLFIRINOX vs 60% wuth SLOG, to achieve 75% power, with a drop-out rate of 10%. Two-sided test was performed with type I error=0.10. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03579836 -
Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient With Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03766295 -
Masitinib Plus Gemcitabine in Pancreatic Cancer
|
Phase 3 | |
| Completed |
NCT00651742 -
Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT01181245 -
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 1 |